Browse AMR Genes
Explore antimicrobial resistance genes from the literature
Explore antimicrobial resistance genes from the literature
SRT/SST family class C beta-lactamase
Overview
| Allele | Database | Papers | Drug Classes | Organisms | Countries | Years | Sequence Accession | Protein Accession |
|---|---|---|---|---|---|---|---|---|
| blaSRT | Reference Gene CatalogReslit | 7 | CEPHALOSPORIN, Piperacillin/tazobactam +2 | Serratia marcescens +1 | Australia|Singapore|Turkey, Spain | 2001, 2004, 2021, 2023, 2025 | AF327324.1 |
| blaSRT-2 | Card DatabaseReference Gene CatalogResFinder DatabaseReslit | 7 | TICARCILLIN, CEPHALOSPORIN +13 | Serratia marcescens +2 | Quebec, Canada, China, Europe | 2004, 2018, 2021, 2024 | AY524276.3 | AAS07017.3 |
| blaSRT-3 | Card DatabaseReference Gene Catalog | 3 | CEPHALOSPORIN | Serratia marcescens | - | 2019 | MG234451.1 | ATN39081.1 |
| blaSST-1 | Card DatabaseReference Gene CatalogResFinder DatabaseReslit | 7 | Piperacillin/tazobactam, TICARCILLIN +10 | Serratia marcescens +3 | Australia|Singapore|Turkey | 1998, 2021 | AB008455.1 | BAA23131.1 |
| bla(SRT-2) | Reslit | 1 | Cephalosporin | Serratia marcescens | China | 2025 | JBMGQM010000000 | - |
| bla_SRT | Reslit | 1 | Ceftazidime, Ceftriaxone +1 | Serratia marcescens +4 | China | 2025 | PRJNA1191627 | - |
| blaSRT-1 | Card DatabaseReference Gene CatalogResFinder DatabaseReslit | 5 | TICARCILLIN, CEPHALOSPORIN +12 | Serratia marcescens +3 | - | 1995, 1998 | AB008454.1 | BAA23130.1 |
| blaSRT-4 | Card DatabaseReference Gene Catalog | 2 | CEPHALOSPORIN | Serratia marcescens | - | - | OK340848.1 | UBX54502.1 |
Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome.
Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate.
Survey of CTX-M-3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan.
Survey of CTX-M-3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan.
Survey of CTX-M-3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan.
Survey of CTX-M-3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan.
Serratia marcescens Outbreak in a Neonatal Intensive Care Unit: New Insights from Next-Generation Sequencing Applications.
The study identified four chromosomal genes associated with antibiotic resistance in Serratia marcescens isolates, including AAC(6′)-Ic, CRP, E. coli CpxR, and SRT-2, which conferred resistance to aminoglycosides and β-lactams.
SME-4-producing Serratia marcescens from Argentina belonging to clade 2 of the S. marcescens phylogeny.
SME-4-producing Serratia marcescens from Argentina belonging to clade 2 of the S. marcescens phylogeny.
Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2).
The study identified several AmpC β-lactamase genes, including bla CMY-2, bla CMY-101, bla CMY-51, bla ACT-17, bla ACT-12, bla ACT-15, bla ACT-16, bla ACT-2, bla ACT-27, bla ACT-38, bla ACT-40, bla ACT-43, bla ACT-49, bla ACT-55, bla CMH-3, bla CMH-1, bla DHA-17, bla DHA-20, bla DHA-12, bla DHA-16, bla DHA-18, bla MIR-18, bla MIR-19, and bla MIR-9, which confer resistance to piperacillin-tazobactam in various Enterobacterales species.
Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2).
The study identified several AmpC β-lactamase genes, including bla CMY-2, bla CMY-101, bla CMY-51, bla ACT-17, bla ACT-12, bla ACT-15, bla ACT-16, bla ACT-2, bla ACT-27, bla ACT-38, bla ACT-40, bla ACT-43, bla ACT-49, bla ACT-55, bla CMH-3, bla CMH-1, bla DHA-17, bla DHA-20, bla DHA-12, bla DHA-16, bla DHA-18, bla MIR-18, bla MIR-19, and bla MIR-9, which confer resistance to piperacillin-tazobactam in various Enterobacterales species.
First Report of bla (IMP-4) and bla (SRT-2) Coproducing Serratia marcescens Clinical Isolate in China.
The study reports the first identification of a Serratia marcescens clinical isolate in China that produces both blaIMP-4 and blaSRT-2, along with other resistance genes such as aac(6')-Ic, qnrS1, and tet(41).
Global population structure of the Serratia marcescens complex and identification of hospital-adapted lineages in the complex.
The study identified multiple antimicrobial resistance (AMR) genes and mutations in the Serratia marcescens complex, highlighting the presence of hospital-adapted lineages with a high prevalence of multidrug-resistant (MDR) strains. Key AMR genes include blaCTX-M, blaNDM, blaOXA, qnrS1, tet(A), aac(6')-Ib, mph(A), erm(B), aadA, floR, sul1, and dfrA12, which confer resistance to various antibiotics such as beta-lactams, fluoroquinolones, tetracyclines, aminoglycosides, macrolides, florfenicol, sulfonamides, and trimethoprim.
Taxonomic Assignment-Based Genome Reconstruction from Apical Periodontal Metagenomes to Identify Antibiotic Resistance and Virulence Factors.
The study identified several antibiotic resistance genes (ARGs) in metagenomic assemblies from apical periodontal infections, highlighting the presence of multidrug resistance mechanisms in Enterobacter and Pseudomonas species.
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone beta-lactamase inhibitors against broad-spectrum AmpC beta-lactamases.
The study evaluates the inhibitory activities of various beta-lactamase inhibitors against a wide range of AmpC beta-lactamases, identifying the effectiveness of certain inhibitors like durlobactam and zidebactam in reducing the MIC values of β-lactam antibiotics against AmpC-producing strains.
Rapid identification of a Serratia marcescens outbreak in a neonatal intensive care unit by third-generation long-read nanopore sequencing.
The study identified several antimicrobial resistance genes in Serratia marcescens isolates, including aac(6'), sdeY, sdeB, smfY, blaSRT, tet(41), blaSHV, and tet(D). These genes contribute to resistance against various antibiotics, highlighting the complexity of the outbreak's genetic profile.
Emergence of carbapenem-resistant Serratia marcescns co-harboring bla(NDM-1), bla(KPC-2), and bla(SRT-2) in bloodstream infection.
The study identifies the first case of a carbapenem-resistant Serratia marcescens strain co-harboring bla(NDM-1), bla(KPC-2), and bla(SRT-2) in China, highlighting the potential for horizontal gene transfer and the challenge of managing multidrug-resistant infections.
Genomic diversity, antimicrobial resistance and dissemination of Serratia marcescens complex in patients admitted to ICUs.
The study identified multiple AMR genes in Serratia marcescens complex isolates, including beta-lactamases (bla_SRT, bla_CTX-M-14, bla_CTX-M-3, bla_CTX-M-15), carbapenemases (bla_KPC-2, bla_NDM-5), and aminoglycoside-modifying enzymes (aac(6')_Serra). These genes were associated with resistance to various antibiotics, including cephalosporins, carbapenems, and aminoglycosides.
A beta-lactamase from Serratia marcescens hydrolyzing the 2-carboxypenam T-5575.
A beta-lactamase from Serratia marcescens hydrolyzing the 2-carboxypenam T-5575.
A beta-lactamase from Serratia marcescens hydrolyzing the 2-carboxypenam T-5575.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
The study identified and characterized two homologous beta-lactamases, SRT-1 and SST-1, from clinical isolates of Serratia marcescens. SRT-1 exhibits resistance to oxyimino cephalosporins, while SST-1 does not. A single amino acid substitution (E213K) in SST-1 conferred the ability to hydrolyze oxyimino cephalosporins, demonstrating the impact of mutations on substrate specificity.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
The study identified and characterized two homologous beta-lactamases, SRT-1 and SST-1, from clinical isolates of Serratia marcescens. SRT-1 exhibits resistance to oxyimino cephalosporins, while SST-1 does not. A single amino acid substitution (E213K) in SST-1 conferred the ability to hydrolyze oxyimino cephalosporins, demonstrating the impact of mutations on substrate specificity.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research